Replimune Wins FDA Accelerated Nod For TUDRIQEVTM In Advanced Melanoma
Replimune Group said the FDA granted accelerated approval for TUDRIQEVTM (vusolimogene oderparepvec-wtpg) with Bristol Myers Squibb’s nivolumab for adults with unresectable advanced cutaneous melanoma after anti-PD-1 therapy. Based on the IGNYTE trial of 140 patients, the regimen reported a 24.2% objective response rate and 14.1-month median duration of response, with mostly mild-to-moderate adverse events.
How this was made
The 30-second read
Why it matters
The FDA decision is based on objective response rate and duration of response from the IGNYTE trial, with continued approval contingent on confirmatory trials. This shifts REPL’s regulatory and clinical risk profile upward while keeping longer-term uncertainty.
Market read
A regulatory approval is a high-impact, time-sensitive biotech catalyst that can drive immediate repricing and trading volume, with follow-through dependent on confirmatory evidence and commercialization.
What to watch
Commercial uptake, pricing/reimbursement, and the design/timeline of confirmatory trials are not detailed here, which can limit how long the initial approval-driven rally lasts.
Background
TUDRIQEVTM (vusolimogene oderparepvec-wtpg) is an oncolytic herpes simplex virus-based immunotherapy given intratumorally every two weeks for eight doses, combined with nivolumab starting week three.
Ticker impact
Replimune received FDA accelerated approval for TUDRIQEVTM plus nivolumab in unresectable advanced cutaneous melanoma after anti-PD-1 progression.
Likely supports continued post-news momentum, but magnitude may fade until confirmatory-evidence milestones or commercial execution details emerge.
The article reports a first-time regulatory milestone (accelerated approval) and cites IGNYTE efficacy metrics and tolerability, which typically improves risk perception for biotech programs while leaving confirmatory-trial uncertainty.
Market effects
Strengthens sentiment for oncolytic immunotherapy and combination regimens in melanoma, potentially improving perceived probability of success for similar platforms.
Primarily US biotech sentiment, with potential spillover to global oncology peers via read-across on FDA willingness to grant accelerated approvals.
May influence international melanoma treatment discussions and investor appetite for immuno-oncology assets globally.
Counterpoint
Accelerated approvals can underperform if confirmatory trials fail or if real-world response rates are weaker than trial endpoints.
Key entities
- companyReplimune Group, Inc.
Company receiving FDA accelerated approval for TUDRIQEVTM plus nivolumab in advanced cutaneous melanoma after anti-PD-1 progression.
- drugTUDRIQEVTM (vusolimogene oderparepvec-wtpg)
Oncolytic immunotherapy granted accelerated approval in combination with nivolumab for unresectable advanced cutaneous melanoma.
- drugNivolumab
Checkpoint inhibitor used in combination with TUDRIQEVTM; administered intravenously starting at week three.
- clinical_trialIGNYTE trial
Trial enrolling 140 patients supporting the accelerated approval; reported ORR 24.2% and median duration of response 14.1 months in the efficacy-evaluable group.
- regulatorU.S. FDA
Granted accelerated approval under the FDA accelerated pathway, with continued approval dependent on confirmatory trials.
